Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy followed by adebrelimab in elderly locally advanced esophageal squamous cell carcinoma
ChiCTR2600122003Phase 4Recruiting
- Sponsor
- The Second Affiliated Hospital of Soochow University
- Start
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adebrelimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The Second Affiliated Hospital of Soochow University. Primary endpoints: Overall Survival, Disease Control Rate and 1 more. Started Apr 2026; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2600122003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122003.